フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation Ad hoc announcement pursuant to art. 53 SIX Swiss...
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio MEDIA RELEASE Afqlir®...
Sandoz reports third-quarter and nine-month 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE...
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position Ad hoc announcement pursuant to art. 53...
Sandoz reports second-quarter sales and half-year 2024 results Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA...
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Ad hoc announcement pursuant to art. 53...
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Ad hoc announcement pursuant to art. 53 SIX Swiss...
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe Ad hoc announcement...
Sandoz reports first quarter 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first...
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG All proposals of Board of...
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Ad hoc announcement pursuant to art...
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering Ad hoc announcement pursuant to...
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines MEDIA RELEASE EUR 50m...
Sandoz reports fourth quarter 2023 sales and full-year 2023 results Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA...
Sandoz receives FDA approval for first and only denosumab biosimilars MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約